|
KMID : 0386420210340040142
|
|
Journal of the Korean Fracture Society
2021 Volume.34 No. 4 p.142 ~ p.147
|
|
|
Denosumab (RANKL Inhibitor): A Potent Anti-Resorptive Agent
|
|
Byun Seong-Eun
|
|
|
Abstract
|
|
|
|
Denosumab, a fully human monoclonal antibody to the receptor activator of nuclear factor-kappa B ligand, was introduced and used as an anti-osteoporotic agent. Denosumab prevents bone resorption by inhibiting the differentiation and action of osteoclasts, resulting in an increase of bone mineral density and broad-spectrum anti-fracture efficacy. Clinical studies, including FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every Six Months) and its extension up to 10 years, FREEDOM Extension, demonstrated its long-term efficacy and safety in postmenopausal osteoporosis. In addition, the efficacy and safety of denosumab were confirmed in male osteoporosis and glucocorticoid- induced osteoporosis. Therefore, recent clinical guidelines recommend denosumab as an initial treatment. This review summarizes the mechanism of action, pharmacological characteristics, efficacy, and safety issue of denosumab.
|
|
|
KEYWORD
|
|
|
Osteoporosis, Denosumab, RANKL (receptor activator of nuclear factor-kappa B ligand
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|